header-logo
MSTP students in the Sahoo lab
Medical Scientist Training Program
Luke Zangl

Luke Zangl

G2 Student

Faculty Advisor

  • Matt Hodges, PhD, Physiology

Locations

  • Medical Scientist Training Program

Contact Information

Education

BS, Neurobiology; Biochemistry, University of Wisconsin-Madison, 2020

Research Interests

Neurophysiology, respiratory physiology

Research Experience

Medical College of Wisconsin, 2023-Present
Advisor: Matthew Hodges, PhD

University of Wisconsin- Madison
Advisor: Zachary Morris, MD, PhD
Project: Utilizing low dose radiation delivered by targeted radionuclides or locally by external beam radiotherapy to augment an array of immunotherapies in treating murine models of cancer

Publications

Jin WJ, Zangl LM, Hyun M, Massoud E, Schroeder K, Alexandridis RA, Morris ZS. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models. J Immunother Cancer. 2023 Sep;11(9):e007474. doi: 10.1136/jitc-2023-007474. PMID: 37730275; PMCID: PMC10510866.

Pieper AA*, Zangl LM*, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, Birstler J, Le T, Carlson PM, Bates AM, Hank JA, Rakhmilevich AL, Erbe AK, Sondel PM, Patel RB, Morris ZS. Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models. Front Immunol. 2021 Nov 15;12:763888. doi: 10.3389/fimmu.2021.763888. PMID: 34868010; PMCID: PMC8634717.

Jagodinsky JC, Jin WJ, Bates AM, Hernandez R, Grudzinski JJ, Marsh IR, Chakravarty I, Arthur IS, Zangl LM, et al. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 2021 Apr 15;11(13):6120-6137. doi: 10.7150/thno.54881. PMID: 33995649; PMCID: PMC8120207.

Bates AM, Brown RJ, Pieper AA, Zangl LM, et al. Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer. Front Oncol. 2021 Apr 15;11:645352. doi: 10.3389/fonc.2021.645352. PMID: 33937052; PMCID: PMC8083981.

Jagodinsky JC, Jin WJ, Bates AM, Hernandez R, Grudzinski JJ, Marsh IR, Chakravarty I, Arthur IS, Zangl LM, et al. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 2021 Apr 15;11(13):6120-6137. doi: 10.7150/thno.54881. PMID: 33995649; PMCID: PMC8120207.

Patel RB, Ye M, Carlson PM, Jaquish A, Zangl L, er al. Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial-Membrane-Coated Nanoparticles. Adv Mater. 2019 Oct;31(43):e1902626. doi: 10.1002/adma.201902626. Epub 2019 Sep 16. PMID: 31523868; PMCID: PMC6810793.

Meeting Abstracts

Zangl LM, Bittencourt-Silva P, Tabor M, Lowe M, Osmani W, Forster H, Hodges MR. Seizures and post-ictal respiratory recovery in Kcnj16-/- Sprague-Dawley Rats. American Physiological Society Annual Meeting, Long Beach, CA. April 2024. [Poster]

Zangl L, Pieper A, Arthur I, Brown RJ, Rakhmilevich A, Sondel P, Morris Z, Patel R. External beam radiotherapy required for tumor regression when using CpG-Oligodeoxynucleotide and anti-Ox40 in an immunologically cold tumor model. American Society for Radiation Oncology, Chicago, IL. Sept 2019. [Oral] 

General Interests

Cooking/baking, film, hiking, kayaking, and loving my cats

© 2024 Medical College of Wisconsin.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The Medical College of Wisconsin (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.